Avalo Therapeutics (AVTX) Expected to Announce Earnings on Thursday

Key Points

• Avalo Therapeutics (AVTX) is set to announce its Q2 2025 earnings results on August 11th, with expectations of reporting a loss of ($1.43) per share.
• The company's previous earnings report showed a miss, with an EPS of ($1.25) compared to an expected ($1.07).
• Avalo Therapeutics has recently received an upgraded rating from "hold" to "buy" by HC Wainwright, with a price target of $15.00.

Avalo Therapeutics (NASDAQ:AVTX - Get Free Report) will likely be releasing its Q2 2025 earnings data before the market opens on Thursday, August 7th. Analysts expect Avalo Therapeutics to post earnings of ($1.43) per share for the quarter.

Avalo Therapeutics (NASDAQ:AVTX - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The company reported ($1.92) earnings per share for the quarter, missing analysts' consensus estimates of ($1.43) by ($0.49). On average, analysts expect Avalo Therapeutics to post $-19 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

Avalo Therapeutics Trading Up 6.9%

Shares of Avalo Therapeutics stock traded up $0.58 during trading hours on Friday, reaching $8.93. The stock had a trading volume of 392,428 shares, compared to its average volume of 284,396. The stock's 50 day moving average is $5.59 and its 200 day moving average is $6.00. Avalo Therapeutics has a twelve month low of $3.39 and a twelve month high of $16.00.

Institutional Trading of Avalo Therapeutics

An institutional investor recently raised its position in Avalo Therapeutics stock. Geode Capital Management LLC boosted its holdings in shares of Avalo Therapeutics, Inc. (NASDAQ:AVTX - Free Report) by 2.5% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 110,460 shares of the company's stock after acquiring an additional 2,648 shares during the period. Geode Capital Management LLC owned 1.02% of Avalo Therapeutics worth $552,000 at the end of the most recent reporting period. 87.06% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Separately, HC Wainwright upgraded shares of Avalo Therapeutics from a "hold" rating to a "buy" rating and set a $15.00 price objective for the company in a research report on Monday, June 2nd. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus target price of $30.00.

Avalo Therapeutics Company Profile

Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.